|
|
|
| High Expression and Immunogenicity Evaluation of Porcine parvovirus VP2 Gene in Silkworm (Bombyx mori) |
| ZHAN Peng-Fei1, DOU Jin-Ping2, YI Yong-Zhu3, LIU Xing-Jian2, LI Yi-Nyu2, FENG Shi-Min1, ZHANG Zhi-Fang2, ZHANG Jin-Wei1 |
1 Huzhou Agricultural Science and Technology Development Center, Huzhou 313000, China;
2 Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China;
3 School of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang 212100, China |
|
|
|
|
Abstract ： Porcine parvovirus (PPV) can cause porcine (Sus scrofa domesticus) reproductive disorder. Vaccination is an effective method to prevent pigs from PPV disease and improve the immunity and reproductive rate of sows. In order to efficiently express PPV structural protein VP2 gene and prepare PPV genetic engineering subunit vaccine, the PPV-VP2 gene was optimized and synthesized according to silkworm (Bombyx mori) codon frequency in this study. The VP2 gene was cloned to transfer vector and recombined into the parental virus BmBacmid with orf1629 gene deficient by co-transfection. The recombinant baculovirus rBmNPV (PPV-VP2) was obtained and used to infect silkworm. The expressed antigen was used to prepare subunit vaccine, and guinea pigs (Cavia porcellus) were used for vaccine efficacy evaluation. The expressed recombinant protein was confirmed by Western blot and mass spectrometry. The observation of electron microscope indicated that the virus like particles (VLP) could be self-assembled into a similar size and morphology to PPV. The results of hemagglutination assay (HA) indicated that expressed antigen titer per gram of silkworm pupae was equivalent to more than 200 doses of commercial vaccine. Guinea pigs were immunized with 3 different doses of PPV-VP2 antigen contents, all inoculated animals had a seroconversion, and the antibody could neutralize PPV in vitro. If a guinea pig was immunized with 5 mg of silkworm pupae (parallel to 200 doses of antigen in commercial vaccine), the hemagglutination inhibition (HI) and neutralizing
|
|
Received: 02 April 2022
|
|
|
|
Corresponding Authors:
*965104@163.com
|
|
|
|
[1] 贾赟, 芦银华, 张素芳, 等. 2004. 猪圆环病毒2 型猪繁殖与呼吸综合征病毒及猪细小病毒混合感染的流行病学调查[J]. 中国病毒学 , 19(5): 467-470.
(Jia Y, Lu Y H, Zhang S F, et al. 2004. Investigation on epidemiology of co-infection of Porcine circovirus type 2, Porcine reproductive and respiratory disease syndrome virus and Porcine parvovirus[J]. Virologica Sinica, 19(5): 467-470.)
[2] 吕建强, 陈焕春, 赵俊龙, 等. 2004. 表达猪细小病毒 VP2 基因的重组伪狂犬病毒的构建及其生物学特征研究[J]. 病毒学报, 20(2): 133-137.
(Lyu J Q, Chen H C, Zhao J L, et al. 2004. The development of recombinant Pseudorabies virus expressing Porcine parvovirus VP2 gene and the study on its biological characters[J]. Chinese Journal of Virology, 20(2): 133-137.)
[3] 刘秀芬, 李一经 . 2010. 猪细小病毒核衣壳 VP2 蛋白单克隆抗体的制备及部分特性鉴定[J]. 中国兽医杂志, 46(5):9-11.
(Liu X F, Li Y J.2010. Development of monoclonal antibodies against VP2 protein of PPV[J]. Chinese Journal of Veterinary Medicine, 46(5): 9-11.)
[4] 盘宝进, 白安斌, 姚瑞英, 等. 2002. 豚鼠对猪细小病毒弱毒苗抗体反应的研究[J]. 中国预防兽医学报, 24(6): 468-470.
(Pan B J, Bai A B, Yao R Y, et al. 2002. Antibody responses of guinea-pigs to attenuated Porcine parvovirus vaccine[J]. Chinese Journal of Preventive Veterinary Medicine, 24(6): 468-470.)
[5] 潘雪珠, 粟寿初, 余晨, 等. 1987. 注射猪细小病毒灭活疫苗的豚鼠的抗体反应[J]. 上海畜牧兽医通讯, 23(4): 4-6.
(Pan X Z, Su S C, Yu C, et al. 1987. Antibody response of guinea pigs injected with Porcine parvovirus inactivated vaccine[J]. Shanghai Journal of Animal Husbandry and Veterinary Medicine, 23(4): 4-6.)
[6] 涂纳新, 张志芳, 郭锡杰, 等. 1994. 应用 PCR 技术诊断家蚕核型多角体病毒病[J]. 蚕业科学, 20(2): 124-125.
(Tu N X, Zhang Z F, Guo X J, et al. 1994. Application of PCR in diagnosis of Bombyx mori polyhedrosis[J]. Acta Sericologica Sinica, 20(2): 124-125.)
[7] 王阿蓉, 侯勇, 龚竞 . 2010. 昆虫贮藏蛋白的研究进展[J]. 蚕学通讯, 30(04): 36-44.
(Wang A R, Hou Y, Gong J.Research progress of insect storage proteins[J]. Newsletter of Sericultural Science, 30(04): 36-44.)
[8] 尹子静 .2011. 国内猪细小病毒疫苗及免疫程序[J]. 畜牧兽医科技信息, (08): 18-20.
(Yin Z J.2011. Domestic Porcine parvovirus vaccine and immunization program[J]. Chinese Journal of Animal Husbandry and Veterinary Medicine, (08): 18-20.)
[9] 周斌, 刘祥, 陈溥言 . 2007. 猪细小病毒分子诊断技术与基因工程疫苗研究进展[J]. 畜牧与兽医 , 39(2): 54-56.
(Zhou B, Liu X, Chen P Y.2007. Review of the molecular diagnosis and gene engineered vaccines in Porcine parvovirus[J]. Animal Husbandry and Veterinary Medicine, 39(2): 54-56.)
[10] 张婉华, 叶向阳, 徐平, 等. 2004. 用豚鼠效检猪细小病毒病油乳剂灭活疫苗判断标准的初步研究[J]. 上海农业学报 , 20(1): 120-122.
(Zhang W H, Ye X Y, Xu P, et al. 2004. Preliminary study on decision standard of testing inactive oil-emulsion Porcine parvovirus vaccine through guinea pigs[J]. Shanghai Agricultural Journal, 20(1): 120-122.)
[11] 中国兽药典委员会. 2011. 中华人民共和国兽药典[M]. 北京: 中国农业出版社, pp. 41. (Chinese Veterinary Pharmacopoeia Committees. 2011. Veterinary Pharmacopoeia of the people's Republic of China[M]. China Agricultural Press, Beijing, China, pp. 41.)
[12] Cui J, Wang X, Ren Y, et al. 2012. Genome sequence of Chinese Porcine parvovirus strain PPV2010[J]. Journal of Virology, 86(4): 2379-2390.
[13] Martínez C, Dalsgaard K, Turiso J, et al. 1992. Production of Porcine parvovirus empty capsids with high immunogenic activity[J]. Vaccine, 10(10): 684-690.
[14] Joo H S, Molitor T W, Leman A D.1984. Antibody responses of guinea-pigs, rabbits and pigs to inactivated Porcine parvovirus vaccines[J]. Veterinary Microbiology, 9(1): 27-33.
[15] Kim J, Chae C.2004. Concurrent presence of porcine circovirus type 2 and Porcine parvovirus in retrospective cases of exudative epidermitis in pigs[J]. Veterinary Journal, 167(1): 104-106.
[16] Sedlik C, Saron M F, Sarraseca J.1997. Recombinant parvovirus-like particles as an antigen carrier: A novel non-replicative exogenous antigen to elicit protective antiviral cytotoxic T cells[J]. Proceedings of the National Academy of Sciences of the USA, 94(14): 7503-7508.
[17] Sedlik C, Dridi A, De Riaud E, et al. 1999. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses[J]. Journal of Virology, 73(4): 2739-2744. |
|
|
|
